Newson Clinic offers UK menopause consultations with different professional and appointment categories. A reader comparing progesterone care should therefore ask two distinct questions: what service is being booked, and what purpose would an added medicine serve after assessment? The public appointment menu answers more of the first question than the second.
We reviewed Newson’s service, consultation and price information on September 29, 2026. The pages name progesterone within a wider hormone discussion, but do not establish the exact oral formulation a patient would receive. This review uses UK guidance to explain the limits of general uterus-history statements without claiming that Newson follows a particular unpublished intake or prescribing protocol.
The appointment offer is a UK clinical service
Newson’s consultation page describes assessment and discussion of hormonal and nonhormonal options. Its service page advertises locations including Stratford-upon-Avon, London and Hale, with video consultations also available. This establishes care beyond general online education. It does not establish eligibility for someone outside the UK or a supply route to another country. Alpha Hormones has a different US geographic offer, so these services should not be treated as interchangeable merely because both discuss progesterone. A prospective patient still needs the provider to confirm the appropriate appointment type, clinician access and any location-related prescribing conditions.
Different clinicians have different published appointment prices
The published appointment cards list an initial doctor appointment at £295 and a doctor follow-up at £230. Initial nurse or pharmacist appointments are £195, with follow-ups at £165. These are consultation fees, not confirmed medication prices or the total cost of a continuing plan. The separate prices-page record did not provide a complete fee table for this review, so it cannot supply missing inclusions or override those cards. The comparison with Myla Health is useful because both publish UK appointment offers; it still requires retaining each service’s exact visit units, medicine charges and follow-up conditions. Booking a follow-up with a particular professional also does not demonstrate that medicine, tests or a later specialist assessment are included. Those questions belong beside the appointment category before a reader uses the advertised fee to compare continuing care.
Combined treatment describes a context, not every estrogen use
NICE menopause recommendations distinguish combined HRT for people with a uterus from estrogen-only HRT following a total hysterectomy, while also directing specialist advice when another condition may be affected by treatment. That guidance should not be reduced to a universal internet instruction. The systemic estrogen discussion helps explain why treatment purpose and history must be considered together. Newson’s public consultation description does not establish what an individual assessment would find. A reader’s existing estrogen, the reason it was prescribed and any other medicines need identification before a general statement can be interpreted meaningfully.
Endometriosis is an example of why the history matters
The British Menopause Society’s February 2026 tool discusses combined therapy in some people with endometriosis after hysterectomy. It also recognizes limited high-quality evidence, the importance of residual disease and case-by-case decisions. That qualification prevents a blanket claim that removal of the uterus always eliminates every possible reason for another hormone. It does not tell a reader which treatment to use or establish Newson’s policy. The questions after hysterectomy focus on clarifying the relevant clinical record. An appointment may need an account of why surgery occurred and what was removed; this review cannot reconstruct those details from a procedure name.
Local exposure has a different evidence boundary
The 2020 NAMS consensus abstract states that a progestogen is not indicated with low-dose vaginal estrogen, but keeps an important limit alongside that conclusion: endometrial safety had not been studied in clinical trials beyond one year. That source is a consensus abstract, not a review of an individual Newson prescription. The local vaginal estrogen guide explains why exact preparation and intended exposure matter. A product used locally for genitourinary symptoms should not automatically be assigned the assumptions of systemic treatment. Nor should the word vaginal alone be taken as confirmation that an unidentified preparation falls within the low-dose statement.
Named hormones do not provide the complete label
Newson’s service information discusses hormones including progesterone, estradiol and testosterone, but that list does not prove which product will be selected or dispensed. NICE’s recommendations address clinical choices and reassessment, not the clinic’s stock, pharmacy arrangements or personal costs. A consultation should leave the patient able to identify each proposed medicine’s purpose and the professional who will review it. If another clinician is expected to continue prescribing, that responsibility also needs agreement. This review does not establish a later NHS prescribing arrangement or assume that naming a commonly used hormone confirms its manufacturer, excipients, route or supply.
A scheduled review does not explain an unexpected symptom
NHS information advises getting postmenopausal bleeding checked even when it occurs only once or consists of a small amount. It explains that the cause is often not serious but can sometimes be cancer. This review cannot decide whether bleeding is related to treatment, and a future follow-up booking does not settle that question. The unexpected bleeding guide supports a professional conversation rather than a regimen change. Newson’s consultation offer remains a verified route to seek care, with the actual clinical purpose, precise preparation and arrangements for concerns between visits still to clarify with the provider.
Sources behind this article
Use the original documents to check their scope. A provider’s offer and a named medicine’s label establish different facts.
- Newson Clinic: ConsultationsUK clinical assessment service; no exact oral medicine, individual eligibility or later NHS prescribing agreement confirmed · Checked 2026-09-29
- Newson Clinic: Menopause care and appointment pricesUK provider service, locations and clinician-specific initial/follow-up price cards; appointment fees are not medicine prices · Checked 2026-09-29
- Newson Clinic: PricesUK provider price-page access record; full fee table absent from returned text, so numeric appointment fees use the separately cited service-page cards · Checked 2026-09-29
- NICE NG23: Menopause, identification and management — recommendationsUK clinical recommendations; systemic/local exposure, total hysterectomy and specialist-history qualifications are not provider-specific protocol or personal treatment directions · Checked 2026-09-29
- British Menopause Society: Induced menopause in women with endometriosis, February 2026UK professional clinical tool, February 2026; post-hysterectomy exceptions depend on residual disease and individual risks, with limited high-quality evidence and case-by-case decisions · Checked 2026-09-29
- NAMS: The 2020 genitourinary syndrome of menopause position statement — abstractPublished professional consensus abstract only; low-dose vaginal estrogen distinction retains absent endometrial-safety clinical trials beyond one year, not a complete-paper or individualized assessment · Checked 2026-09-29
- NHS: Postmenopausal bleedingUK public patient guidance, reviewed September 24, 2026; bleeding assessment advice does not diagnose a cause or transfer NHS referral timings to US services · Checked 2026-09-29